Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03605914
Other study ID # HSC-MS-18-0242
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date August 1, 2018
Est. completion date July 5, 2020

Study information

Verified date July 2021
Source The University of Texas Health Science Center, Houston
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the level of pain control in patients receiving non-steroidal anti-inflammatory drugs (NSAIDs) to those receiving opioids in the postoperative period after endoscopic sinus surgery (ESS) and/or septoplasty.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date July 5, 2020
Est. primary completion date July 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - english speaking - candidates for endoscopic sinus surgery as determined by medical necessity by the treating rhinologist - scheduled for surgery at Texas Sinus Institute Exclusion Criteria: - allergy to either NSAIDs or opioids - contraindication to NSAIDs (ex. gastritis, chronic kidney disease) - surgical plan exceeding basic endoscopic sinus surgery - use of anticoagulation - the presence of any pain disorder - the current usage of any analgesic medication - history of opioid addiction - pregnancy - history of chronic pain or fibromyalgia - current daily use of NSAIDs, acetaminophen, opioids or other analgesics (pregabalin, tramadol, etc)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
diclofenac
The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
Norco
The opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).

Locations

Country Name City State
United States The University of Texas Health Science Center at Houston Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Score as Assessed by a 100mm Visual Analogue Scale (VAS) The range of scores on the VAS is 0 to 100, with 100 being the highest level of pain. 24 hours (day 1 after operation)
Secondary Pain Score as Assessed by a 100mm Visual Analogue Scale (VAS) The range of scores on the VAS is 0 to 100, with 100 being the highest level of pain. 48 hours (day 2 after operation)
Secondary Pain Score as Assessed by a 100mm Visual Analogue Scale (VAS) The range of scores on the VAS is 0 to 100, with 100 being the highest level of pain. 72 hours (day 3 after operation)
Secondary Pain Score as Assessed by a 100mm Visual Analogue Scale (VAS) The range of scores on the VAS is 0 to 100, with 100 being the highest level of pain. 120 hours (day 5 after operation)
Secondary Number of Participants With Bleeding Complications Bleeding complications are defined as complications necessitating a trip to the emergency room or requiring intervention for epistaxis. 5 days after operation
Secondary Number of Participants With Constipation 5 days after operation
Secondary Number of Participants With Nausea or Vomiting 5 days after operation